Download the Corporate Factsheet (PDF) - MorphoSys

Factsheet
January 2013
Engineering the Medicines of Tomorrow
The Company
MorphoSys is a biotechnology company focused on the develop -
ment and application of antibodies. Using its proprietary techno -
logies, the Company develops and commercializes high-quality
antibodies for therapeutic. By combining in-house development
with selected strategic alliances, MorphoSys has built one of the
industry’s broadest pipelines of therapeutic antibody candi dates.
The Company’s business model combines the commer cialization
of its proprietary technologies with funded collaborations as a
means of financing proprietary development. The strong cashflows
the business generates enable MorphoSys to fund all of
its proprietary R&D activities and to record solid operating profits.
This sound financial performance distinguishes MorphoSys from
many other companies in the industry.
Business Strategy
MorphoSys operates in two business segments.
The Partnered Discovery segment operates in partnerships with
pharmaceutical and biotechnology companies, applying the
Company’s proprietary technologies to generate new drug candidates.
While the development costs are borne by the partner,
MorphoSys secures research funding and technology license
fees, and stands to benefit from successful programs through
mile stone payments and royalties on product sales. By way of
example, the Company’s strategic alliance with Novartis is one
of the largest R&D agreements ever signed in the pharma ceutical
industry.
The second segment, Proprietary Development, also operates in
the pharmaceutical industry. The goal of this segment is to apply
the Company’s technologies to make new therapeutic antibody
candidates and develop them as far as clinical proof-of-concept
before partnering. The focus is on indications such as inflammatory
and autoimmune diseases, as well as infectious di seases
and oncology. In each program there is a clear focus on in novative
approaches to diseases which are currently not well-treated.
Technologies
MorphoSys’s success is based on the HuCAL platform, a techno -
logy comprising several billion distinct, fully human antibodies
which can be optimized for specific applications. Currently, more
than 70 therapeutic antibodies derived from HuCAL are in
develop ment, 21 of which are in clinical testing.
Through its 2010 acquisition of Sloning BioTechnology,
MorphoSys became the sole source of Sloning’s state-of-the-art
Slonomics technology, which dramatically improves the assembly
and quality of protein libraries. This technology is used to
accelerate the generation of therapeutic antibodies and is at
the core of MorphoSys’s newest antibody technology Ylanthia.
Ylanthia was specifically designed to overcome current
limitations in therapeutic antibody development, including
challenges associated with certain target classes, limited diversity,
poor biophysical properties and difficult production.
In 2012, MorphoSys launched a new initiative through which
the Company provides innovation capital to promising start-ups
with technologies and product candidates being close to its areas
of interest. MorphoSys seeks to combine the classical cor porate
venture approach with collaborative elements. In 2012, MorphoSys
announced a first collaboration in this area with Lanthio
Pharma, a biopharmaceutical company focused on discovering
and developing lantipeptides.
MORPHOSYS AG
n Stock Exchange Frankfurt, Germany, TecDAX 30
n Security Code Number MOR/663200
n ISIN DE 0006632003
n U.S. Security Code (Cusip) 617760103 (MPSYY)
n No. of Shares Issued (Sept. 30, 2012) 23,308,622
n No. of Employees Corporate Group (Sept. 30, 2012) 422
n Revenues 2011 (IFRS) EUR 100.8 million
n Net Income 2011 (IFRS) EUR 8.2 million
n Diluted Net Profit per Share 2011 (IFRS) EUR 0.36

Product Pipeline
Program, Partner Indication Discovery Pre-clinic Phase 1 Phase 2 Phase 3 Market
MOR10 3 Rheumatoid Arthritis
MOR103 Multiple Sclerosis
MOR208 B-cell Malignancies
MOR202 Multiple Myeloma
Gantenerumab, Roche Alzheimer’s Disease
CNTO 888, Janssen/J&J Immunology
CNTO 1959, Janssen/J&J Psoriasis
CNTO 1959, Janssen/J&J Rheumatoid Arthritis
BHQ880, Novartis Cancer
BYM338, Novartis Musculoskeletal
NOV-3, Novartis n. d.
LGF316, Novartis Ophthalmology
OMP-59R5, OncoMed Cancer
BAY94-9343, Bayer HealthCare Cancer
BI-1, Boehringer Ingelheim Cancer
CNTO 3157, Janssen/J&J Asthma
CNTO-5, Janssen/J&J Inflammation
VAY736, Novartis Inflammation
LJM716, Novartis Cancer
Vantictumab, OncoMed Cancer
PFE-1, Pfizer Cancer
1. Partnered Products
MorphoSys’s partnered product pipeline comprises more than
60 antibody programs covering a range of indications. The pipeline
spans a number of successful partnerships which have been
established over the last 12 years since the HuCAL technology
was introduced. Of the programs in development, 17 are pre -
sently in human clinical trials and around 20 in preclinical
evaluation.
2. Proprietary Products
MorphoSys develops proprietary therapeutic antibody candidates
in the areas of inflammation, infectious diseases and oncology.
By conducting the discovery, pre-clinical and early clinical
development itself, MorphoSys is building a valuable portfolio
of proprietary drugs. The Company plans to take these compounds
to clinical proof-of-concept before seeking a partner for
subsequent development and commercialization.
Currently, the proprietary product portfolio comprises the following
clinical stage programs:
MOR103
MOR103 is a HuCAL antibody directed against GM-CSF, a thera -
peutic target for the treatment of inflammatory diseases that
has great potential in a number of indications where current
treat ments are inadequate. MOR103 is the first anti-GM-CSF
antibody to demonstrate clinical efficacy in rheumatoid arthritis.
A clinical phase 1b/2a study in patients with RA has been
CONTACT
MorphoSys AG
Lena-Christ-Str. 48
82152 Martinsried/Planegg
Germany
Phone: +49 (0) 89 899 27-0
Fax: +49 (0) 89 899 27-222
Email: info@morphosys.com
Website: www.morphosys.com
completed and reported excellent data on safety and efficacy in
September 2012. In addition to the RA trial, MOR103 is currently
being tested in a phase 1b trial in patients with multiple
sclerosis.
MOR202
MOR202 is a HuCAL antibody directed against CD38, a promising
therapeutic target for the treatment of multiple myeloma
and certain leukemias. In pre-clinical studies, MOR202 effectively
killed cancer cells from primary patient tumor material and
showed very effective inhibition of tumor growth in a SCIDmouse
tumor model. MOR202 is currently being tested in a
phase 1/2a trial in multiple myeloma patients.
MOR208
MOR208 is a humanized monoclonal antibody in-licensed from
Xencor, which targets the antigen CD19. The antibody incor -
porates an optimized Fc portion, which further enhances its ability
to kill malignant CD-19-bearing B-cells. MOR208 is being
developed for the treatment of B-cell malignancies and autoimmune
diseases. The program has concluded a phase 1 trial in
patients with CLL and will now advance into phase 2 studies in
ALL and NHL.
Management
Management Board
Dr. Simon E. Moroney, Chief Executive Officer
Jens Holstein, Chief Financial Officer
Dr. Arndt Schottelius, Chief Development Officer
Dr. Marlies Sproll, Chief Scientific Officer
HuCAL ® , HuCAL GOLD ® , HuCAL PLATINUM ® , CysDisplay ® , RapMAT ® , arYla ® , Ylanthia ® and 100 billion high potentials ® are registered trademarks of MorphoSys AG.
Slonomics ® 2013
January
is a registered trademark of Sloning BioTechnology GmbH, a subsidiary of MorphoSys AG. Version: